Dare Bioscience

Dare Bioscience Working Capital

The Working Capital of Dare Bioscience (DARE) as of Oct 31, 2026 is 22.46 M USD. In the previous year, Working Capital was 9.58 M USD — a change of 134.44% (higher).

Working Capital

22.46 MUSD

YoY

134.44%

Last updated:

Working Capital of Dare Bioscience is 2025 22.46 M USD. Working Capital of Dare Bioscience was 2024 9.58 M USD. It decreases by 134.44% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Working Capital of Dare Bioscience is 22.46 M USD in 2025.

Working Capital of Dare Bioscience changed from 9.58 M USD to 22.46 M USD, representing a 134.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Dare Bioscience

All Key Metrics — Dare Bioscience